grant Funding Outcomes
ACH4 Expressions of Interest (EoI)
ach4 funding
Results Summary
Over the past 20 years, ACH4 has supported translational research in the areas of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) and now human T-lymphotropic virus type-1 (HTLV-1).
In 2025, ACH4 will continue to support translational research into these four viral infections.
A public call for applications from Australian organisations for the Centre (EOI) grants will be advertised through a variety of forums. The next call for EOI will be made in mid 2025.
ACH4 EoI > Round 2024-2025
The SAC met on 13 November 2024 and reviewed 35 applications in this Round. It recommends 10 applications for funding (noting that there were additional EOIs that merited funding). This comprises a success rate of 29%.
Summary:
- Amount available: $500K
- 10 grants-in-aid recommended
- Total applications: 35
- Overall success rate: 29%
Success rates of applications by category of application:
- Antiviral targets 30%
- Diagnostics/prognostics 33%
- Vaccines/prevention/immunotherapy 23%
ACH4 EoI > Round 2023-2024
The SAC met on 27 October 2023 and reviewed 37 applications in this Round. It recommends 10 applications for funding (noting that there were additional EOIs that merited funding). This comprises a success rate of 27%.
Summary:
- Amount available: $500K
- 10 grants-in-aid recommended
- Total applications: 37
- Overall success rate: 27%
Success rates of applications by category of application:
- Antiviral targets 25%
- Diagnostics/prognostics 25%
- Vaccines/prevention/immunotherapy 31%
ACH4 EoI > Round 2022-2023
The SAC met on 18 October 2022 and reviewed 24 applications in this Round. It recommends 10 applications for funding (noting that there were additional EOIs that merited funding). This comprises a success rate of 42%.
Summary:
- Amount available: $500K
- 10 grants-in-aid recommended
- Total applications: 24
- Overall success rate: 42%
Success rates of applications by category of application:
- Antiviral targets 44%
- Diagnostics/prognostics 38%
- Vaccines/prevention/immunotherapy 43%
ACH4 EoI > Round 2021-2022
The SAC met on 8 October 2021 and reviewed 36 applications in this Round and recommends 17 grants for funding (noting that there were additional EOIs that merited funding). This comprises a success rate of 47%.
Summary:
- Amount available: $1.66K
- 17 full grants recommended
- Total applications: 36
- Overall success rate: 47%
Success rates of applications by category of application:
- Antiviral targets 57%
- Diagnostics/prognostics 41%
- Vaccines/prevention/immunotherapy 30%
ACH4 EoI > Round 2020-2021
The SAC met on 4 December 2020 reviewed 34 applications in this Round and recommends 14 grants for funding (noting that there were additional EoIs that merited funding). This comprises a success rate of 41%.
Summary:
- Amount available: $1.259M
- 12 full / 2 partial / 1 grant-in-aid recommended
- Total applications: 34
- Overall success rate: 44%
Success rates of applications by category of application:
- Antiviral targets 46%
- Diagnostics/prognostics 36%
- Vaccines/prevention/immunotherapy 50%
ACH4 EoI > Round 2019-2020
The SAC met on 25 November 2019 and reviewed 63 applications in this Round and recommends 23 grants for funding (noting that there were additional EoIs that merited funding). This comprises a success rate of 37%.
Summary:
- Amount available: $1.654M
- 17 full / 2 partial / 4 grant-in-aid recommended
- Total applications: 63
- Overall success rate: 37%
Success rates of applications by category of application:
- Antiviral targets 38%
- Diagnostics/prognostics 32%
- Vaccines/prevention/immunotherapy 38%
ACH4 EoI > Round 2018-2019
The SAC met on 23 November 2018 and reviewed 59 applications in this Round and recommends 19 grants for funding (noting that there were more EoIs that merited funding). This comprises a success rate of 32%.
Summary:
- Amount available: $1.637M
- 17 full / 2 grants-in-aid recommended
- Total applications: 59
- Overall success rate: 32%
Success rates of applications by category of application:
- Antiviral targets 25%
- Diagnostics/prognostics 45%
- Vaccines 25%
- Immunotherapy 42%
